SPR720: Novel Oral Mycobacterial Therapy – Oral Presentation Posted on June 24, 2019 at 3:14 pm.Written by Spero Therapeutics View Presentation Post navigation Single-and Multiple-Ascending Dose (SAD/MAD) Study Demonstrates the Human Pharmacokinetics (PK) and Tolerability of SPR994 (Tebipenem Pivoxil hydrobromide), an Oral Carbapenem (CP), at the Predicted Therapeutic DoseIn Vitro Activity of SPR719 against Non-Tuberculosis Mycobacterium Strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera – Pipeline Drugs to Treat Gram-positive, C. Difficile and Non-TB Mycobacterial Infections – Oral Presentation
